Literature DB >> 31063194

Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study.

Junichi Ishigami1, Ron C Hoogeveen2, Christie M Ballantyne2, Aaron R Folsom3, Josef Coresh1, Elizabeth Selvin1, Kunihiro Matsushita1.   

Abstract

Whether persons without prevalent cardiovascular disease (CVD) but elevated levels of high-sensitivity cardiac troponin T (hs-cTnT) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) are at high risk of infection is unknown. Using 1996-2013 data from the Atherosclerosis Risk in Communities Study, we estimated hazard ratios for incident hospitalization with infection in relation to plasma hs-cTnT and NT-proBNP concentrations among participants without prevalent CVD and contrasted them with hazard ratios for persons with prevalent CVD (coronary heart disease, heart failure, or stroke). In a multivariable Cox model, prevalent CVD was significantly associated with risk of hospitalization with infection (hazard ratio (HR) = 1.31, 95% confidence interval (CI): 1.19, 1.45). Among participants without prevalent CVD, hs-cTnT and NT-proBNP were independently associated with infection risk in a graded fashion (e.g., HR = 1.44 (95% CI: 1.24, 1.69) for hs-cTnT ≥14 ng/L and HR = 1.28 (95% CI: 1.14, 1.44) for hs-cTnT 9-13 ng/L vs. <3 ng/L; HR = 1.57 (95% CI: 1.35, 1.81) for NT-proBNP ≥248.1 pg/mL and HR = 1.19 (95% CI: 1.06, 1.34) for NT-proBNP 137.2-248.0 pg/mL vs. <48.1 pg/mL). The 15-year cumulative incidences of hospitalization with infection were similar for participants with prevalent CVD and participants who did not have prevalent CVD but had hs-cTnT ≥14 ng/L or NT-proBNP ≥248.1 pg/mL. Thus, hs-cTnT and NT-proBNP were independently associated with infection risk. Persons without CVD but with elevated hs-cTnT or NT-proBNP levels should be recognized to have similar infection risks as persons with prevalent CVD.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  N-terminal pro-B-type natriuretic peptide; cardiovascular disease; high-sensitivity cardiac troponin T; hospitalization; infection

Mesh:

Substances:

Year:  2019        PMID: 31063194      PMCID: PMC7212398          DOI: 10.1093/aje/kwz113

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  47 in total

Review 1.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications.

Authors:  Robb D Kociol; Peter S Pang; Mihai Gheorghiade; Gregg C Fonarow; Christopher M O'Connor; G Michael Felker
Journal:  J Am Coll Cardiol       Date:  2010-09-28       Impact factor: 24.094

2.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

3.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-10-12       Impact factor: 17.586

Review 4.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.

Authors:  Jenny A Doust; Eva Pietrzak; Annette Dobson; Paul Glasziou
Journal:  BMJ       Date:  2005-03-19

5.  Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Aaron R Folsom; Lu Yao; Alvaro Alonso; Pamela L Lutsey; Emil Missov; Frank A Lederle; Christie M Ballantyne; Weihong Tang
Journal:  Circulation       Date:  2015-06-17       Impact factor: 29.690

6.  Prevention and Control of Seasonal Influenza with Vaccines.

Authors:  Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Sonja J Olsen; Ruth A Karron; Daniel B Jernigan; Joseph S Bresee
Journal:  MMWR Recomm Rep       Date:  2016-08-26

7.  Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data.

Authors:  Jennifer Drahos; Jeffrey J Vanwormer; Robert T Greenlee; Ola Landgren; Jill Koshiol
Journal:  Ann Epidemiol       Date:  2013-03-22       Impact factor: 3.797

Review 8.  Regulatory T cells in cardiovascular diseases.

Authors:  Xiao Meng; Jianmin Yang; Mei Dong; Kai Zhang; Eric Tu; Qi Gao; Wanjun Chen; Cheng Zhang; Yun Zhang
Journal:  Nat Rev Cardiol       Date:  2015-11-03       Impact factor: 32.419

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  Multistate point-prevalence survey of health care-associated infections.

Authors:  Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

View more
  2 in total

1.  High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Junichi Ishigami; Yuhree Kim; Yingying Sang; Steven P Menez; Morgan E Grams; Hicham Skali; Amil M Shah; Ron C Hoogeveen; Elizabeth Selvin; Scott D Solomon; Christie M Ballantyne; Josef Coresh; Kunihiro Matsushita
Journal:  Clin Chem       Date:  2021-01-08       Impact factor: 8.327

2.  Early-Warning Immune Predictors for Invasive Pulmonary Aspergillosis in Severe Patients With Severe Fever With Thrombocytopenia Syndrome.

Authors:  Lifen Hu; Qinxiang Kong; Chengcheng Yue; Xihai Xu; Lingling Xia; Tingting Bian; Yanyan Liu; Hui Zhang; Xuejiao Ma; Huafa Yin; Qiulin Sun; Yufeng Gao; Ying Ye; Jiabin Li
Journal:  Front Immunol       Date:  2021-05-07       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.